Seattle, WA – May 9, 2025 – Seattle Scientific Analysis Heart (SCRC) is proud to share {that a} new therapy for migraine—Atzumi™ (dihydroergotamine) nasal powder—has been authorized by the U.S. Meals and Drug Administration (FDA) for the acute therapy of migraine with or with out aura in adults. SCRC was one of many scientific trial websites for the pivotal Part III ASCEND research, which evaluated the long-term security and tolerability of Atzumi in adults dwelling with migraine.
Developed by Satsuma Prescribed drugs, Atzumi is the first and solely DHE (dihydroergotamine) nasal powder to obtain FDA approval. Designed for ease of use and portability, Atzumi affords a brand new supply technique for a time-tested treatment that has been used to deal with migraine because the Forties. The product makes use of Satsuma’s proprietary SMART (Easy Muco-Adhesive Launch Expertise) platform, combining a complicated powder formulation with a user-friendly gadget to simplify DHE supply.
Not like injectable or liquid nasal spray types of DHE—which could be inconvenient or poorly tolerated by some sufferers—Atzumi gives a needle-free various that achieves fast and sustained absorption with low variability. This makes it a very necessary choice for people who want efficient migraine aid even later in an assault.
Migraine impacts an estimated 40 million Individuals and is acknowledged because the second main reason for incapacity worldwide. Its signs—extreme headache, nausea, sensitivity to mild and sound—can considerably affect an individual’s high quality of life, work, and relationships. For a lot of sufferers, quick and dependable acute therapy is vital. The approval of Atzumi expands the toolbox for clinicians and sufferers on the lookout for new choices to handle migraine episodes extra successfully.
The FDA’s approval of Atzumi was primarily based on outcomes from each a pharmacokinetic Part 1 research and the ASCEND Part 3 open-label security trial. The trials demonstrated favorable outcomes when it comes to absorption price, plasma focus of DHE, and long-term security. SCRC’s function within the ASCEND trial underscores the positioning’s continued dedication to advancing migraine analysis and bringing novel therapies to those that want them most.
About Seattle Scientific Analysis Heart
Seattle Scientific Analysis Heart is a number one scientific analysis facility devoted to advancing healthcare choices, searching for medical breakthroughs for humanity, and offering compassionate care to each research participant. Our state-of-the-art analysis facility, positioned within the coronary heart of Seattle, makes a speciality of scientific trials for situations that considerably affect high quality of life, together with migraine. This milestone serves as a robust reminder of the worth of scientific analysis and the vital contributions of research contributors, who make developments like this doable.
To be taught extra about ongoing scientific trials at Seattle Scientific Analysis Heart, go to SeattleCRC.com/Research.
